We studied urinary nitrate and cGMP excretion rates, indices of systemic. NO formation, and plasma concentrations of 1.-arginine and the endogenous NO synthase inhibitor asymmetrical dimethylarginine (ADMA) and its inactive stereoisomer, symmetrical dimethylarginine, in 77 patients with peripheral arterial occlusive disease (PAOD) in Fontaine stages IIb through IV and in 47 young and 37 elderly healthy control subjects.
Bockground
We studied urinary nitrate and cGMP excretion rates, indices of systemic. NO formation, and plasma concentrations of 1.-arginine and the endogenous NO synthase inhibitor asymmetrical dimethylarginine (ADMA) and its inactive stereoisomer, symmetrical dimethylarginine, in 77 patients with peripheral arterial occlusive disease (PAOD) in Fontaine stages IIb through IV and in 47 young and 37 elderly healthy control subjects.
Merhods and Results
Urinary nitrate excretion was 182.0211.4 pnoUmmol creatinine and cGMP excretion was 186.2113.0 nrnoUmrno1 creatinine in young healthy control subjects. In elderly control subjects, both excretion rates were slightly lower (nitrate, 156.027.8 ~mollmmol creatinine; cGMP, 150.0C8.3 nmollmmol creatinine: P=NS). In PAOD patients, there was a significant, progressive reduction of urinary nitrate (114 138.4C11. Exogenous administration of L-arginine has been shown to restore, at least in part, the physiological activity of NO in experimental hypercholesterolemia. 4.8 However, the mechanism leading to impaired NO activity in the atherosclerotic vascular wall has not yet been fully elucidated. One explanation for decreased NO formation, which can be restored by exogenous L-arginine, may be the accumulation of endogenous NOS inhibitors. ADMA has been characterized as an endogenously occumng NOS inhihitor. 9 In hypercholesterolemic rabbits, plasma concentrations of endogenous of PAOD. These changes were independent of changes in renal excretory function. Plasma L-arginine concentrations were not significantly different between the groups, but ADMA concentrations were elevated in PAOD patients (young control subjects, 1.2510.11; elderly control subjects, 1.01CO.05 &mollL; IIb, 2.6220.24; 111, 3.0620.48: and IV, 3.4910.26 (Finnigan MAT) . An OV-l fused silica capillary column (25 mX0.25 mm ID, 0.25-fim film thickness) from Machery-Nagel was used with helium as the carrier gas (55 kPa). Negative ions were produced hy chemical ionization with methane as the reactant gas (65 Pa) at an electron e n e r a of 90 eV and an electron current of 0.2 mA. Quantification was performed by selected ion monitoring at m/z of 46 for endogenous NO1-/NO; and mb of 47 for the internal standard. The detection limit of the method was 20 fmol nitrite or nitrate. Intra-assay variability was below 3.8%.
For the determination of cGMP. urine samples weIe diluted 1500 in PBS and acetylated with a mixture o f acetic acid anhydrideitriethylamine. cGMP content was measured by radioimmunoassay using "'I-labeled cGMP as a tracer and globulin precipitation. The detection limit of the assay was 160 fmollmL.
Urinary and plasma creatinine were determined spectrophotometrically with the alkaline picric acid method in an automatic analyzer (Beckman). The urinary excretion rates of NO,-and cGMP were corrected by urinary creatinine concentration to limit the variability due to differences in renal excretory function as described previously.84.17
Determination of Plasma L-Arginine and DMA Concentrations
Plasma L-arginine and DMA concentrations were determined by HPLC using precolumn derivatization with OPA as described previously." Plasma samples and standards were extracted on CBA solid-phase extraction cartridges (Varian). The eluents were dried over nitrogen and dissolved in bidistilled water for HPLC analysis. HPLC was carried out on a Gynkotek liquid chromatography system consisting o f two HPLC pumps with a gradient controller (model M 480 HDG), a spectral fluorescence detector RF 1002, and an automatic injector (model GINA 160). Samples and standards were incubated for exactly 30 seconds with the OPA reagent (5.4 mdmL OPA in borate buffer, pH 8.5, containing 0.4% 2-mercaptoethanol) before automatic injection into the HPLC. The OPA derivatives of r-arginine, ADMA and SDMA, were separated on a C6H5 column (Macherey and Nagel) with the fluorescence monitor set at hc'=340 nm and h'"=455 nm. Samples were eluted from the column with 0.96% citric acid! methanol 21, pH 6.8, at a Row rate ol 1 mlimin. The coefficients of variation of the method had previously been determined to be 5.2% within-assay and 5.5% between-assay; the detection limit of the assay was 0.1 pmoliL.
Calculations and Statistics
All values are given as mean2SEM. Statistical significance was tested with ANOVA followed by Fisher's protected least significant difference test for comparisons between treatment groups. Linear regression cuwes and correlation coefficients were obtained by the least-squares method. Statistical significance was accepted at the .05 level of probability.
Results

Urinary NO3-and cGMP Excretion Rates
Urinary NO; excretion was 182.0211.4 +molimmol creatinine (1861.2?113.1 pmo1124 h) in young healthy volunteers. In elderly control subjects, urinary NO,-excretion was 156.027.8 ptnollmmol c r e a t i n i n e (1717.2246.0 pmo1124 h; P=NS versus young healthy subjects). In PAOD patients, urinaly N03-excretion was In all subjects selected for the study. venous blood was cuilrcted in the morning after an overnight fast. The blood was separated within I hour after collection. and the plasma was kept f m r m at -20°C until analysis. Twenty-four-hour urine samples were collected from all subjects at the same time. lsopropanol was added to the urine sampling containers in an amount to reach a final concentration of 10% to 15C, (vol/vol) in urine to inhibit bacterial activity. We have previously demonstrated that this amount of isopropanol does not interfere with the N O j and cGMP assays.l"" In the patients, urine and plasma samples were obtained on day 2 after hospitalization, just before any active treatment was started, to exclude any inHuences from ambulatory medication or diet or from any interventional therapy.
Quantification of Urinary NO,-and cGMP
Urinary NOl-lTiO,-was determined as its pentaHuorobenzyl derivative by GC-MS as described previously.li-'~ Briefly, aliquots of urine were spiked with ["N]NO; (MSD Isotopes (Fig 1A) .
Urinary cGMP excretion was 186.2213.0 nmollmmol creatinine in young healthy volunteers and 150.0-C8.3 nmol/mmol creatinine in elderly control subjects (2399.12155. 9 and 2019 .8+70.9 nmo1/24 h, respectively; P=NS). In PAOD patients, urinary cGMP excretion was also significantly lower than in young or elderly control subjects (114. 35 12.8 nmollmmol creatinine, 1392 .62140.7 nmoV24 h; P<.05) (Fig lB) .
When PAOD patients were stratified according to the Fontaine classification of PAOD, a stage-dependent decrease in mean urinary NO; and cGMP excretion rates was observed (Fig 2) : Patients with intermittent claudication (Fontaine stage 11) had only a slight reduction in both urinary NO; and cGMP excretion rates, which was not significantly ditferent from elderly control subjects, whereas in patients with resting pain ( Interestingly, in all study groups, urinary NO3-and cGMP excretion rates were higher in female than in male subjects. Although the differences between the two sexes did not reach statistical significance in any single group of subjects, there was a significant overall trend toward higher values in women than in men (P<.05 in multiple regression analysis).
Creatinine clearance was 135.423.7 mumin in young control subjects. It was significantly lower in elderly control subjects, btit there was no significant difference henveen PAOD patients and elderly control subjects ( Table 7) . Plasma cholesterol levels are given in Table 2 . None of the young or elderly control subjects had hypercholesterolemia. hut hypercholesterolemia was a common risk factor in PAOD patients (see Table I ). Table 3 ) . Elaated ADMA plasma concentrations resulted in significantly decreased L-arginine:ADMA ratios in PAOD patients compared with young or elderly control subjects (Fig 3) .
In multiple regression analysis, ADMA plasma concentrations were dependent on plasma total cholesterol levels (r=.336: P<.Ool) and on creatinine clearance (r=.322:
P<.OI).
However, when subgroups of elderly control subjects and PAOD patients with normal or impaired renal hnction were compared. there was only a slight, insipificmt further increase in mean plasma ADMA that could be ascribed to impaired renal excretion (Fig 4) . PAOD patients with normal renal function (creatinine clearance, 113.223.6 mumin) had a mean ADMA plasma concentration of 2.6320.25 fimol/L. whereas in PAOD patients with impaired renal function (creatinine clearance, 60. 3-3.3 Discussion Our present study suggests that systemic NO formation. as assessed by measurement of urina? NO;-excretion rates. is decreased in patients with PAOD. This decrease in urinary NO:-excretion is dependent on the severity of PAOD (as measured by rhe Fontaine classification): it is paralleled by decreased urinaly cGMP excretion. an index of NO activity. Plasma concentrations of DMAs. endogenous NOS inhibitors. are concomitantly increased in PAOD.
It is well known that the biologicdl activity of endothelium-derived NO is impaired in patients with atherosclerotic vascular diseases. This has usually been assessed hy measurement of endothelium-dependent vascular dilatations in the or forearm vascular beds."'." However. the cause leading to this defect has remained unclear (for review. see Reference 22).
Discussion has focused primarily on the question of whether there is a decreased NOS activity, which may he due to decreased endothelial NOS Ill gene expression or impaired NOS substrate availability1".'3 or increased oxidative degradation of NO, eg, by superoxide anions'4.'5 in atherosclerotic blood vessels.22 Our present data suggest that systemic NO production is decreased in patients with PAOD. because the urinan excretion rates of both NO,-and cGMP are significantl! and stage-dependently decreased compared with health! control subjects. These results are in line with o u r previous finding that urinan NO; excretion proyressively decreased during tho induction of atherosclerosis in cholesterol-fed rabhits.' Howe~er. some in vitro studies in isolated aortic rinzs from cholesterol-fed rabbits suggest that the production of nitrogen oxides is increased.", Our approach of noninvasively measuring NO:^ and cGMP excretion rates allows us to differentiate henveen decreased NO production and enhanced NO inactivation. because urinary NO; indicates the endogenous formation rate of NO irrespective of whether this NO was biologically active orwhether it had been inactivated early (NO oxidatively inactivated by 0:-is also converted into the final metabolite, NO?). In contrast. urinan cGMP excretion indicates the biological activity of NO, because only the portion of NO that exerts its biological etfects on the soluble guanylyl cyclase will increa.se cGMP levels. Therefore. if oxidative degradation of NO were the main cause of decreased NO activity in PAOD patients, one should have expected a decreased urinary cGMP excretion in the presence of normal NO; excretion.
P<.02).
T A~L E
In this respect, it is important to note that the relative decrease in urinary cGMP excretion with progression of PAOD was greater than for NO:.. impact on the accelerated in;ictivation of NO.:: Moreover. leukocytes are capahle of synthesizing NO hy the iNOS isoenzyme.' There is evidence that iNOS is induced in atherosclerotic blood vessel hanced iNOS-derived NO formation ma another explanation for relatively higher urinary nitrate excretion rates compared with cGMP excretion rates.
Decreased systemic NO formation in atherosclerosis may he due to decreased NOS gene expression Or decreased NOS enzyme activity. Decreased enzyme activity may he related to decreased intracellular L-arginine availability in the vicinity of the NOS. We h a w recently shown that plasma concentrations of ADMA. an endogenousNOS inhibitor."are increased in hypercholesterolemic rabbits." The ADMA plasma concentxitions we found in our group of hralthy young volunteers were v e n close to those previously reported hy Vallance et al .:" for healthy humans (1.15?0.19 pmo1.L). Our present study is the first to report elevated plasma concentrations of ADMA and SDMA in humans with atherosclerotic vascular disease. Elevated .ADMA levels in atherosclerotic patients resulted in a disease stas+ dependent deterioration of the plasma L-arginine .ADMA ratio. Vallance et all" reported elerated DMA plaxma concentrations in patients with chronic rend failure and suggested that DMA levels increase in thesc patients because of diminished renal excretion. This finding was in line with biochemical eiidence that DM.As are uliminated via the kidneys in hedrh! mimals.'l H m u v c r . ADMA plasma concentration5 are elevxed in h~pereli~~lestcr~~lemic rahhits despite normal renal cxcreton function.""l In our present study. n u found that the elevation of ADMA plasma concentrations in PAOD patients was also present in those patients with normal rennl function. whereas elderly c~n t r o l subjects with moderately impaired renal function had no significant increase in ADMA plasma concentrarions. The discrepan? with the findings of Vallance and coworke r P ma) relate to the fact that they studied patients with end-stage renal failure undergoing hemodialysis. in whom there may have been virtually no renal elimination of DMA5 at all. whereas in our patients with moderately reduced cieatinine clearances. residual DMA escretion may have been fairly high. Therefore. enhanced endogenous ADMA synthesis probably contributes at least in part to its elevated plasma concentrations in atherosclerosis. The ADMA plasma concentrations we found in PAOD patients were in the ranye of concentrations that have previously been shown to inhibit NO production in cultured macrophages.3' in rat mesentery tissue.'2 and in rat brain.'"
The origin of the methyl groups of DMAs is currently unknown. Physiological DMA plasma concentrations in healthy animal5 stem from degradation of the corresponding methylated proteins.'' It is not clear whether there is enhanced degradation of tissue proteins in PAOD. possihl! caused hy ischemia of peripheral s ketiil musclcs. Thih. however. would not explain a h y DMA conccntr;itions are a1x1 eloxted in lh!percholesterolemic rahhits. DMA is metabolized by dimet nasu t i 1 citrulliiiu i n cultured endothelial cell inipairnicnt oi t h i h n1et:ihiilizing pathway uould alho iiicrciisc Dhl.-\ c~wcnlriitioii~. Another pohsihlc. soiircc oi u l c w c d D51A ciinccntriitioiis ma! he increased methylation of L-arginine. which has also been ohsewed in cultured endothelial cells.ii Utilization of L-arginine hy ii mrrhylating metabolic pathway might also explain its decreased availability as a substrate for the NOS. Although the precise concentrations of DMAs within cells are not known, it has brrn reported that methyl-;ir:inines are concentrated within cells." Therefore, the relatively small increase in plasma ADMA concentration in patients with PAOD in our present study may mirror an even higher i n c r e w of this compound in the vicinity of the NOS.
Several studies have demonstrated in recent years that L-arginine induces NO-dependent vasodilatation in humans.".'" However, because basal L-arginine plasma lrvels by far exceed the half-maximal substrate concentration for the endothelial NOS. whose K, has heen determined in vitro to be 2.9 pm01IL.j~ and the estimated intracellular concentration of 1-arsinine in early-passaged rndothelial cells is likely to he in the low millimolar range? the mechanism by which Larginine might exert its hcmodynamic effects in atherosclerotic patients has remained unclea:. Impaired UOS activity due to accumulation of endogenou, inhibitors like ADMA might explain in part the mechanism of action of L-arginine: It would act h ! competing with ADMA for the NOS and. by displacing it from the enzyme, restore NOS activity anti normalize NO production.
In conclusion. our present study shows that systemic NO synthesis rates gradually decrease in patients with PhOD while the clinical symptoms increase. Decreased NO formation may be at least partly due to increased plasma concentrations of ADMA. an endogenous NOS inhibitor. These results may explain why L-arginins induces vasodiliitation in atherosclerosis and thus solve rhe T-argininc paradox" in patirnts with generalized atherosclerosis.
